136 related articles for article (PubMed ID: 17214601)
1. Potential protective properties of a stable, slow-releasing nitric oxide donor, GEA 3175, in the lung.
Laursen BE; Stankevicius E; Pilegaard H; Mulvany M; Simonsen U
Cardiovasc Drug Rev; 2006; 24(3-4):247-60. PubMed ID: 17214601
[TBL] [Abstract][Full Text] [Related]
2. Inhibition by nitric oxide-releasing compounds of prostacyclin production in human endothelial cells.
Kosonen O; Kankaanranta H; Malo-Ranta U; Ristimäki A; Moilanen E
Br J Pharmacol; 1998 Sep; 125(2):247-54. PubMed ID: 9786495
[TBL] [Abstract][Full Text] [Related]
3. Mode of cytostatic action of mesoionic oxatriazole nitric oxide donors in proliferating human hematopoietic cells.
Vilpo JA; Vilpo LM; Vuorinen P; Moilanen E; Metsä-Ketelä T
Anticancer Drug Des; 1997 Mar; 12(2):75-89. PubMed ID: 9113063
[TBL] [Abstract][Full Text] [Related]
4. Dual impact of a nitric oxide donor, GEA 3175, in human pulmonary smooth muscle.
Elmedal B; Mulvany MJ; Simonsen U
Eur J Pharmacol; 2005 May; 516(1):78-84. PubMed ID: 15899479
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of relaxations of bovine isolated bronchioles by the nitric oxide donor, GEA 3175.
Hernández M; Elmedal B; Mulvany MJ; Simonsen U
Br J Pharmacol; 1998 Mar; 123(5):895-905. PubMed ID: 9535018
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of mesoionic 3-aryl substituted oxatriazole-5-imine derivatives on vascular smooth muscle cell mitogenesis and proliferation in vitro.
Lähteenmäki T; Sievi E; Vapaatalo H
Br J Pharmacol; 1998 Sep; 125(2):402-8. PubMed ID: 9786515
[TBL] [Abstract][Full Text] [Related]
7. Nitric oxide as a regulator of prostacyclin synthesis in cultured rat heart endothelial cells.
Sievi E; Lähteenmäki TA; Alanko J; Vuorinen P; Vapaatalo H
Arzneimittelforschung; 1997 Oct; 47(10):1093-8. PubMed ID: 9368700
[TBL] [Abstract][Full Text] [Related]
8. Dual actions of dephostatin on the nitric oxide/cGMP-signalling pathway in porcine iliac arteries.
Persson AA; Gunnarsson P; Lindström E; Grenegård M
Eur J Pharmacol; 2005 Oct; 521(1-3):124-32. PubMed ID: 16182278
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide-releasing compounds inhibit neutrophil adhesion to endothelial cells.
Kosonen O; Kankaanranta H; Malo-Ranta U; Moilanen E
Eur J Pharmacol; 1999 Oct; 382(2):111-7. PubMed ID: 10528145
[TBL] [Abstract][Full Text] [Related]
10. Cross-talk between adenosine and the oxatriazole derivative GEA 3175 in platelets.
Asplund Persson A; Zalavary S; Lindström E; Whiss PA; Bengtsson T; Grenegård M
Eur J Pharmacol; 2005 Jul; 517(3):149-57. PubMed ID: 15963495
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of mesoionic oxatriazole derivatives in blood, cardiovascular and respiratory systems.
Corell T; Pedersen SB; Lissau B; Moilanen E; Metsä-Ketelä T; Kankaanranta H; Vuorinen P; Vapaatalo H; Rydell E; Andersson R
Pol J Pharmacol; 1994; 46(6):553-66. PubMed ID: 7542520
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of GEA 3175 on human platelets; comparison with S-nitroso-N-acetyl-D,L-penicillamine.
Asplund Persson AK; Palmér L; Gunnarsson P; Grenegård M
Eur J Pharmacol; 2004 Aug; 496(1-3):1-9. PubMed ID: 15288569
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide-releasing compounds inhibit the production of interleukin-2, -4 and -10 in activated human lymphocytes.
Korhonen R; Kosonen O; Hämäläinen M; Moilanen E
Basic Clin Pharmacol Toxicol; 2008 Oct; 103(4):322-8. PubMed ID: 18684225
[TBL] [Abstract][Full Text] [Related]
14. NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties.
Momi S; Impagnatiello F; Guzzetta M; Caracchini R; Guglielmini G; Olivieri R; Monopoli A; Gresele P
Eur J Pharmacol; 2007 Sep; 570(1-3):115-24. PubMed ID: 17632098
[TBL] [Abstract][Full Text] [Related]
15. In-vitro bronchorelaxing effects of novel nitric oxide donors GEA 3268 and GEA 5145 in guinea-pigs and rats.
Vaali K; Li L; Redemann B; Paakkari I; Vapaatalo H
J Pharm Pharmacol; 1996 Dec; 48(12):1309-14. PubMed ID: 9004196
[TBL] [Abstract][Full Text] [Related]
16. GEA 3162 decomposes to co-generate nitric oxide and superoxide and induces apoptosis in human neutrophils via a peroxynitrite-dependent mechanism.
Taylor EL; Rossi AG; Shaw CA; Dal Rio FP; Haslett C; Megson IL
Br J Pharmacol; 2004 Sep; 143(1):179-85. PubMed ID: 15289284
[TBL] [Abstract][Full Text] [Related]
17. Effects of the nitric oxide-donor, GEA 3175, on guinea-pig airways.
Johansson Rydberg IG; Andersson RG; Grenegård M
Eur J Pharmacol; 1997 Jun; 329(2-3):175-80. PubMed ID: 9226411
[TBL] [Abstract][Full Text] [Related]
18. Effect of a new nitric oxide donor on the biomechanical performance of the isolated ischaemic rat heart.
Szekeres M; Dézsi L; Monos E; Metsä-Ketelä T
Acta Physiol Scand; 1997 Sep; 161(1):55-61. PubMed ID: 9381950
[TBL] [Abstract][Full Text] [Related]
19. Protein disulphide isomerase-mediated LA419- NO release provides additional antithrombotic effects to the blockade of the ADP receptor.
Vilahur G; Pena E; Padró T; Badimon L
Thromb Haemost; 2007 Apr; 97(4):650-7. PubMed ID: 17393029
[TBL] [Abstract][Full Text] [Related]
20. Nitrosyl-cobinamide, a new and direct nitric oxide releasing drug effective in vivo.
Broderick KE; Alvarez L; Balasubramanian M; Belke DD; Makino A; Chan A; Woods VL; Dillmann WH; Sharma VS; Pilz RB; Bigby TD; Boss GR
Exp Biol Med (Maywood); 2007 Dec; 232(11):1432-40. PubMed ID: 18040067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
